Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134663) titled 'PSMA PET delayed imaging guides the clinical treatment decision-making of patients with biochemical recurrent prostate cancer' on Oct. 19.
Study Type: Diagnostic test
Study Design:
Diagnostic test for accuracy
Primary Sponsor: West China Hospital, Sichuan University
Condition:
Prostate cancer
Intervention:
Gold Standard:1. For operable patients, the pathology from reoperation after biochemical recurrence serves as the reference gold standard.
2. For inoperable patients, the gold standard is the core needle biopsy pathology.
3. For inoperable patients who are not eligible for biopsy, the reference standard i...